Who
Nadia Dac
Chief Commercial Officer
Company insider
Files Form 4 as: Chief Commercial Officer, Kyverna Therapeutics; Chief Commercial Officer, Alder Biopharmaceuticals.
In numbers
- Trades disclosed
- 4
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 8 Apr 2019
- Last trade
- 4 May 2026
- Last filed
- 6 May 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 May 2026filed 6 May 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 4 May 2026filed 6 May 2026 | KYTX Kyverna Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 22 Oct 2019filed 24 Oct 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code D | —250,000 at $0.00 | filing |
| 8 Apr 2019filed 10 Apr 2019 | Alder Biopharmaceuticalsoption or derivative | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.